BLCM - ベリカム・ファ―マシュ―ティカルズ （Bellicum Pharmaceuticals Inc.）

HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Thursday reported a loss of $7.6 million in its first quarter. The Houston-based company said it had a loss of 25 cents per share. In the final minutes of trading on Thursday, the company''s shares hit $1.43. A year ago, they were trading at $2.95. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLCM at https://www.zacks.com/ap/BLCM

Bellicum Pharmaceuticals press release (BLCM): Q1 GAAP EPS of -$0.25 beats by $0.42.Bellicum reported cash and cash equivalents and restricted cash totaling $41.3 million as of March…

HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.

HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Thursday reported a loss of $7.6 million in its first quarter. The Houston-based company said it had a loss of 25 cents per share. In the final minutes of trading on Thursday, the company''s shares hit $1.43. A year ago, they were trading at $2.95. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLCM at https://www.zacks.com/ap/BLCM

Bellicum Pharmaceuticals press release (BLCM): Q1 GAAP EPS of -$0.25 beats by $0.42.Bellicum reported cash and cash equivalents and restricted cash totaling $41.3 million as of March…

HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.

In todays recent session, 0.77 million Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) shares changed hands as the companys beta touched 1.52. With the companys per share price at $1.53 changed hands at -$0.16 or -9.47% during last session, the market valuation stood at $14.91M. BLCMs last price was a discount, traded about -432.68% off its 52-week high Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM): This Is The Year For Success Over The Next Few Months Read More »

(RTTNews) - Bellicum Pharmaceuticals, Inc. (BLCM) reported positive interim data from ongoing phase 1/2 GoCAR-T clinical trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Charity Scripture, Chief Development Officer of Bellicum, said: "The early clinical activity we

Squarepoint Ops LLC cut its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 41.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,327 shares of the biopharmaceutical companys stock after selling 11,588 shares during the quarter. Squarepoint Ops LLC []